PDL-1 inhibitors

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete
Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete
SF Gate, CA
Regeneron
PDL-1 inhibitors
cemiplimab
Flag link:
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
ASCO
IDO inhibitors
CAR-T
PDL-1 inhibitors
Merck
Incyte
NewLink Genetics
Novartis
Juno Therapeutics
Bristol-Myers Squibb
Flag link:
Bristol-Myers takes a commanding lead over Merck in the first stretch of a blockbuster race
Bristol-Myers takes a commanding lead over Merck in the first stretch of a blockbuster race
Endpoints
Bristol-Myers Squibb
Merck
Keytruda
Opdivo
PDL-1 inhibitors
Flag link:
Epizyme partners with Roche to test cancer drug combo
Epizyme partners with Roche to test cancer drug combo
BioPharma Dive
Epizyme
Roche
PDL-1 inhibitors
diffuse large B-cell lymphoma
Tecentriq
tazemetostat
Flag link:
Five Storylines To Watch At ASCO
Five Storylines To Watch At ASCO
Forbes
ASCO 2016
drug pricing
Pfizer
Ibrance
breast cancer
Tecentriq
Genentech
Roche
PDL-1 inhibitors
Flag link:
AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
Fierce Biotech
AstraZeneca
durvalumab
PDL-1 inhibitors
lung cancer
Flag link:
Keytruda's label confers edge for Opdivo
Keytruda's label confers edge for Opdivo
Medical Marketing and Media
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
PDL-1 inhibitors
Flag link:
The Biggest Selling Cancer Drugs In 2020 Show Significant Change Expected In Five Short Years
The Biggest Selling Cancer Drugs In 2020 Show Significant Change Expected In Five Short Years
Forbes
ASCO
PDL-1 inhibitors
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Flag link:
A preview of the new lung cancer data Roche will debut at ASCO
A preview of the new lung cancer data Roche will debut at ASCO
BioPharma Dive
non-small cell lung cancer
ASCO
Roche
Genentech
MPDL3280A
PDL-1 inhibitors
Flag link:
Novartis grabs Zykadia approval in Europe, setting the stage for PD-L1 showdown
Novartis grabs Zykadia approval in Europe, setting the stage for PD-L1 showdown
Fierce Pharma
Novartis
Zykadia
Europe
Pfizer
Xalkori
PDL-1 inhibitors
Flag link:
Merck's Keytruda shrinks lung cancer tumors, FDA approval sought
Merck's Keytruda shrinks lung cancer tumors, FDA approval sought
Yahoo/Reuters
Merck
Keytruda
lung cancer
FDA
non-small cell lung cancer
PDL-1 inhibitors
Flag link:
New cancer drugs "vastly overestimated", says contrarian analyst
New cancer drugs "vastly overestimated", says contrarian analyst
Yahoo/Reuters
cancer
PD-1 inhibitors
PDL-1 inhibitors
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Flag link: